- In May 2024, Donaldson Company, Inc. and PolyPeptide Group AG have partnered to develop a large-scale solvent recovery system for peptide purification. Peptides, used as APIs, are expanding in therapeutic areas such as oncology, metabolic disorders, and neurology. This collaboration will enhance production efficiency, reducing costs and supporting the growing demand for peptide-based therapies
- In April 2024, CordenPharma and GENEPEP, in their 2023 partnership, are combining CordenPharma's cGMP manufacturing and regulatory expertise with GENEPEP's strengths in peptide drug discovery and development. This collaboration supports biotech companies in advancing peptides through early clinical phases. It will enhance the companies' capabilities in delivering high-quality peptide therapies while accelerating time-to-market for innovative treatments
- In March 2024, AstraZeneca has reached an agreement to acquire Amolyt Pharma, a clinical-stage biotech focused on rare endocrine diseases. This acquisition will strengthen the Alexion Rare Disease pipeline and expand its bone metabolism portfolio with eneboparatide (AZP-3601), a Phase III investigational peptide for hypoparathyroidism. It will enhance AstraZeneca’s position in rare disease treatments, particularly in bone metabolism, and support its growth in this specialized therapeutic area
- In January 2024, WuXi AppTec expanded its manufacturing capabilities with two new peptide plants in Changzhou and Taixing, China, increasing solid-phase peptide synthesis reactor volume to 32,000 L. The plants will feature digital systems and automated solvent delivery to optimize production and reduce cycle time. This expansion will enhance production efficiency, improve scalability, and help meet the growing demand for peptide-based therapeutics
- In November 2023, Novo Nordisk has announced plans to invest over 42 billion Danish kroner from 2023 onward to expand its manufacturing facilities in Kalundborg, Denmark, primarily focusing on increasing active pharmaceutical ingredient (API) capacity along with packaging capabilities. This investment is expected to enhance the company's global production capacity, enabling it to meet the rising demand for its products and support future growth
